Slide 1

Slide 2

Slide 3
Slide 4

Slide 5

Slide 6
Slide 7

Slide 8

Slide 9
Slide 10

Slide 11

Slide 12
Slide 13

Slide 14

Slide 15
Slide 16

Slide 17

Slide 18
Slide 19

Slide 20

Slide 21
Slide 22

Slide 23

Slide 24
Slide 25

Slide 26

Slide 27
Slide 28

Slide 29

Slide 30
Slide 31

Slide 32

Slide 33
Slide 34

Slide 35

Slide 36
Slide 37

Slide 38

Slide 39
Slide 40

Slide 41

Slide 42
Slide 43

Slide 44

Slide 45
Slide 46

Slide 47

Slide 48
Slide 49

Slide 50

Slide 51
Slide 52 In an acute HBV infection, symptoms
last from 10 to 20 weeks after
infection. Before symptoms appear
HBsAg and HBeAg are detectable in
the bloodstream. Antibodies against
HBeAg are detectable about 4 months
after infection. Initially, anti-HBcAg
antibodies are IgM but this wanes
although total anti-HBcAg continues at
a high level. HBsAg is detectable in the
bloodstream from one to six months
after infection, but anti-HBsAg is only
detectable from about 8 months.
Thus, there is a "window" in which
neither HBsAg nor anti-HBsAg
antibodies can be detected.

Slide 53 In a chronic infection, HBsAg and

HBeAg are detectable throughout the
course of the infection. Anti-HBcAg
(again initially IgM) and anti-HBeAg
are also detectable
Slide 54

Slide 55

Slide 56 To detect viral proteins in serum or

clinical samples, a capture antibody,
directed against the protein, is linked
to a solid support such as a plastic 96
well microtiter plate , or a bead. The
clinical specimen is added, and if viral
antigens are present, they will be
captured by the bound antibody. The
bound viral antigen is then detected
by using a second antibody linked to
an enzyme. A chromogenic molecule –
one that is converted by the enzyme
to an easily detectible product – is
then added. The enzyme amplifies the
signal because a single catalytic
enzyme molecule can generate many
 product molecules.

Slide 57 To detect antibodies to viruses, viral

protein is linked to the plastic support,
and then the clinical specimen is
added. If antibodies against the virus
are present in the specimen, they will
bind to the immobilized antigen. The
bound antibodies are then detected
by using a second antibody that binds
to the first antibody.

Slide 58
Slide 59

Slide 60 the sample migrates from the sample

pad through the conjugate pad where
any target analyte present will bind to
the conjugate. The sample then
continues to migrate across the
membrane until it reaches the capture
zone where the target/conjugate
complex will bind to the immobilised
antibodies producing a visible line on
the membrane. The sample then
migrates further along the strip until it
reaches the control zone, where
excess conjugate will bind and
produce a second visible line on the
membrane. This control line indicates
that the sample has migrated across
the membrane as intended. Two clear
lines on the membrane is a positive
result. A single line in the control zone
is a negative result.
Slide 61

Slide 62

Slide 63 Specific nature of these pairings allows

one strand of DNA or RNA to specify
the nucleic acid sequence of a
complementary sequence.
Slide 64

Slide 65

Slide 66
Slide 67

Slide 68

Slide 69
Slide 70

Slide 71

Slide 72
Slide 73

Slide 74

Slide 75
Slide 76

Slide 77

Slide 78
Slide 79

Slide 80

Slide 83
Slide 84

Slide 85

Slide 86
Slide 87

Slide 88

Slide 89
Slide 90

Slide 91

Slide 92
Slide 93

Slide 94

Slide 95
Slide 96

Slide 97

Slide 98
Slide 99

Slide 100

Slide 101
Slide 102